Gene Morse

Summary

Affiliation: University at Buffalo
Country: USA

Publications

  1. pmc Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals
    Gene D Morse
    Adult ACTG Pharmacology Support Laboratory, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, University at Buffalo, Amherst, NY 14260, USA
    Antimicrob Agents Chemother 49:3373-81. 2005
  2. ncbi request reprint Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy
    Gene D Morse
    Department of Pharmacy Practice, University at Buffalo, State University of New York, Amherst 14260, USA
    Lancet Infect Dis 6:215-25. 2006
  3. pmc Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa
    Fatai A Fehintola
    Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Nigeria
    Curr Drug Metab 12:51-6. 2011
  4. ncbi request reprint Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application
    Kim Keil
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
    Ther Drug Monit 29:103-9. 2007
  5. ncbi request reprint Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users
    Robin DiFrancesco
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
    J Pharm Biomed Anal 44:188-95. 2007
  6. ncbi request reprint Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring
    Judianne Slish
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Ther Drug Monit 29:560-5. 2007
  7. ncbi request reprint Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir
    Niamh Higgins
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Am J Addict 16:488-94. 2007
  8. ncbi request reprint Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma
    Kim Keil
    Department of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14260, USA
    Ther Drug Monit 25:340-6. 2003
  9. pmc Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients
    Mark J Shelton
    Laboratory for Antiviral Research, Department of Pharmacy Practice, University at Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1694-9. 2003
  10. pmc Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects
    Robert Dicenzo
    University at Buffalo, Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1929-35. 2003

Detail Information

Publications48

  1. pmc Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals
    Gene D Morse
    Adult ACTG Pharmacology Support Laboratory, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, University at Buffalo, Amherst, NY 14260, USA
    Antimicrob Agents Chemother 49:3373-81. 2005
    ..7 to 1.0; P = 0.042). African-American non-Hispanics had higher day 14 efavirenz AUCs than white non-Hispanics. We conclude that EFV lowered APV AUCs, but nelfinavir, indinavir, or ritonavir compensated for EFV induction...
  2. ncbi request reprint Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy
    Gene D Morse
    Department of Pharmacy Practice, University at Buffalo, State University of New York, Amherst 14260, USA
    Lancet Infect Dis 6:215-25. 2006
    ..Current investigation is focused on examining the predictive value of this approach for clinical monitoring...
  3. pmc Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa
    Fatai A Fehintola
    Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Nigeria
    Curr Drug Metab 12:51-6. 2011
    ....
  4. ncbi request reprint Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application
    Kim Keil
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
    Ther Drug Monit 29:103-9. 2007
    ..During 2 years, more than 100 batches of analyses have been performed and have proved the method is rugged, specific, and accurate. This assay method is currently used in the authors' clinical research program in TDM...
  5. ncbi request reprint Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users
    Robin DiFrancesco
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
    J Pharm Biomed Anal 44:188-95. 2007
    ..Use of this combined BUP and ARV plasma concentration monitoring approach for a representative patient receiving BUP, atazanavir and efavirenz demonstrated its clinical application...
  6. ncbi request reprint Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring
    Judianne Slish
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Ther Drug Monit 29:560-5. 2007
    ..Further work is needed to assess the optimal dosing regimen when using LPV in HIV-infected substance users...
  7. ncbi request reprint Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir
    Niamh Higgins
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Am J Addict 16:488-94. 2007
    ..These data indicate that chronic HIV treatment may be assisted with plasma concentration monitoring to identify those patients who may require dosage modification and/or regimen adjustment in order to optimize antiretroviral effects...
  8. ncbi request reprint Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma
    Kim Keil
    Department of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14260, USA
    Ther Drug Monit 25:340-6. 2003
    ..1 to 0.2 microg/mL with an interday variation in CV ranging from 3.5% to 10.4%. The method is being applied to a TDM program that is currently being implemented in the authors' laboratory...
  9. pmc Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients
    Mark J Shelton
    Laboratory for Antiviral Research, Department of Pharmacy Practice, University at Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1694-9. 2003
    ..h, and a C(min) of 9.1 +/- 7.5 micro M. Therefore, delavirdine increases systemic exposure to ritonavir by 50 to 80% when the drugs are coadministered...
  10. pmc Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects
    Robert Dicenzo
    University at Buffalo, Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1929-35. 2003
    ..Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h...
  11. ncbi request reprint A dose-ranging study of a methylphenidate transdermal system in children with ADHD
    William E Pelham
    State University of New York at Buffalo, NY, USA
    J Am Acad Child Adolesc Psychiatry 44:522-9. 2005
    ..Medication (placebo, 0.45, 0.9, and 1.8 mg/h) was crossed with application time (6 a.m., 7 a.m.) to evaluate MTS efficacy and influence of exposure time on morning effects...
  12. ncbi request reprint Advances in pharmacogenomics of antiretrovirals: an update
    Qing Ma
    Pharmacotherapy Research Center, University at Buffalo, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY 14260, USA
    Pharmacogenomics 8:1169-78. 2007
    ..Future directions for research and the application of this technology to the clinical practice of individualizing treatment for HIV management are discussed...
  13. pmc Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial
    Robin DiFrancesco
    Department of Pharmacy Practice, SUNY at Buffalo, Buffalo, NY, USA
    Ther Drug Monit 32:458-66. 2010
    ..The application of some of these findings may also be relevant to single-center studies or clinical TDM programs within a hospital...
  14. ncbi request reprint Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode array
    Kim Keil
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
    Ther Drug Monit 28:512-6. 2006
    ..390 microg/mL with an interday variation in control value ranging from 2.9 to 4.6%. The method is being used in a clinical therapeutic drug monitoring program that is ongoing in our laboratory...
  15. ncbi request reprint Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry
    Valerie A Frerichs
    Pharmacotherapy Research Center, Core Analytical Laboratory, Department of Pharmacy Practice, University at Buffalo, State University of New York, Room 317 Hochstetter Hall, Buffalo, NY 14260 1200, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 787:393-403. 2003
    ..The evolution of complex drug interactions assessments and the clinical use of therapeutic drug monitoring for these antiretrovirals will be a potential immediate application of this method...
  16. ncbi request reprint Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry
    Robin DiFrancesco
    Department of Pharmacy Practice, University at Buffalo, NY 14260, United States
    J Pharm Biomed Anal 44:1139-46. 2007
    ..The method successfully measured LPV concentrations in CSF that were previously undetectable by HPLC as well as UF from protein binding studies...
  17. ncbi request reprint Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals
    Patrick F Smith
    Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 219 Cooke Hall, Buffalo, NY 14260, USA
    Clin Pharmacokinet 44:99-109. 2005
    ..Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies...
  18. ncbi request reprint Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV
    Qing Ma
    University at Buffalo, Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, NY, USA
    Pharmacogenomics 8:227-35. 2007
    ..We examined MDR1 single nucleotide polymorphisms in a cohort of patients in whom therapeutic drug monitoring is ongoing through a research protocol...
  19. pmc Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
    Patrick F Smith
    Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
    Antimicrob Agents Chemother 49:3558-61. 2005
    ..There were no significant differences in efavirenz pharmacokinetics...
  20. ncbi request reprint Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers
    Qing Ma
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14260, USA
    Biopharm Drug Dispos 29:91-101. 2008
    ..In conclusion, concomitant administration of dual PIs is unlikely to have any clinically significant effect on the pharmacokinetics of CYP2B6 substrates in general or oral efavirenz specifically...
  21. ncbi request reprint Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors
    Qing Ma
    University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA
    Expert Opin Drug Metab Toxicol 1:473-85. 2005
    ..This review provides an updated summary of pharmacokinetic interactions with NNRTIs...
  22. ncbi request reprint Drug interactions between proton pump inhibitors and antiretroviral drugs
    Sarah M McCabe
    Associate Dean, Clinical Education and Research, University of Buffalo, Department of Pharmacy Practice, 317 Hochstetter Hall, Buffalo, NY 14260, USA
    Expert Opin Drug Metab Toxicol 3:197-207. 2007
    ..This review summarizes the current knowledge on the interactions between proton pump inhibitors and antiretrovirals, and makes recommendations for the coadministration of proton pump inhibitors...
  23. ncbi request reprint Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment
    Sarah M McCabe
    Department of Pharmacy Practice and Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY 14260, USA
    Clin Pharmacokinet 47:153-72. 2008
    ..This review summarizes the current knowledge of the use of antiretrovirals in patients with hepatic or renal impairment, and makes dosing recommendations for this subpopulation of HIV-infected patients...
  24. pmc Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects
    Robert Dicenzo
    University at Buffalo, Buffalo, New York 14260, USA
    Antimicrob Agents Chemother 48:918-23. 2004
    ..5 to 5,540 ng/ml). Due to the unacceptable number of undetectable indinavir trough concentrations, 1200 mg of indinavir appears to be the preferred dose in a twice-daily regimen that includes nelfinavir...
  25. ncbi request reprint Drug interactions with antiretrovirals
    Linda M Catanzaro
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, NY 14260, USA
    Curr HIV/AIDS Rep 1:89-96. 2004
    ..This review provides an updated summary of key drug interactions that have been reported since its initial publication...
  26. pmc Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks
    Olanrewaju Okusanya
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 317 Hochstetter Hall, Amherst, NY 14260, USA
    Antimicrob Agents Chemother 51:1822-6. 2007
    ..The nature of the secondary peaks may be an important consideration for the interpretation of amprenavir plasma concentrations during therapeutic drug monitoring...
  27. ncbi request reprint Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers
    Desiree L Tomilo
    School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
    Pharmacotherapy 26:341-6. 2006
    ..To determine whether the pharmacokinetics of atazanavir, a protease inhibitor used to treat human immunodeficiency virus (HIV) infection, are altered by its coadministration with lansoprazole, a proton pump inhibitor...
  28. ncbi request reprint Data from clinical trials
    Linda M Catanzaro
    Laboratory for Antiviral Research, ACTG Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, New York, USA
    J Acquir Immune Defic Syndr 38:S26-9. 2005
  29. ncbi request reprint Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints
    Robin DiFrancesco
    Department of Pharmacy Practice, University at Buffalo, Buffalo, New York 14260, USA
    HIV Clin Trials 7:203-9. 2006
    ..To achieve this goal, a tutorial was designed to improve the accuracy and completeness of data collected in ACTG pharmacology protocols...
  30. ncbi request reprint Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity
    Mark J Shelton
    GlaxoSmithKline, Five Moore Drive, P O Box 1398, Research Triangle Park, NC 27709, USA
    J Clin Pharmacol 43:171-9. 2003
    ..HIV-infected subjects with gastric hypoacidity significantly malabsorb delavirdine. Delavirdine administration with acidic beverages improves, but dose not normalize, absorption in these subjects...
  31. ncbi request reprint Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection
    Robert W Shafer
    Stanford University Medical Center, Stanford, Calif, USA
    N Engl J Med 349:2304-15. 2003
    ..It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens...
  32. pmc The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients
    Lisa M Demeter
    Infectious Diseases Division, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    HIV Clin Trials 9:61-72. 2008
    ....
  33. ncbi request reprint Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine
    Elinore F McCance-Katz
    Virginia Commonwealth University, Richmond, USA
    Clin Infect Dis 43:S224-34. 2006
    ..Adjustments of doses of either buprenorphine or EFV or DLV are not likely to be necessary when these drugs are administered for the treatment of opiate dependence and HIV disease...
  34. pmc Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    C Bradley Hare
    Dept of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 47:421-4. 2008
    ..Mutations remained detectable for at least 48 weeks in some subjects...
  35. ncbi request reprint A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir
    Scott M Hammer
    Columbia University, New York, NY, USA
    Antivir Ther 8:507-18. 2003
  36. ncbi request reprint A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease
    Margaret A Fischl
    Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
    J Infect Dis 188:625-34. 2003
    ..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity...
  37. ncbi request reprint Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
    David W Haas
    Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Infect Dis 192:1931-42. 2005
    ..Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment...
  38. pmc Interaction between buprenorphine and atazanavir or atazanavir/ritonavir
    Elinore F McCance-Katz
    Virginia Commonwealth University, Richmond, VA, USA
    Drug Alcohol Depend 91:269-78. 2007
    ..Atazanavir or atazanavir/ritonavir may increase buprenorphine and buprenorphine metabolite concentrations and might require a decreased buprenorphine dose...
  39. ncbi request reprint Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine
    Elinore F McCance-Katz
    Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Am J Addict 15:23-34. 2006
    ....
  40. ncbi request reprint Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir
    Troy M Martin
    AIDS 20:1085-7. 2006
  41. ncbi request reprint Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA 02215, USA
    HIV Clin Trials 8:19-23. 2007
    ....
  42. ncbi request reprint Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir
    Elinore F McCance-Katz
    Virginia Commonwealth University, Richmond, USA
    Clin Infect Dis 43:S235-46. 2006
    ..Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease...
  43. ncbi request reprint Pharmacokinetic interactions between buprenorphine and antiretroviral medications
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT 06511, USA
    Clin Infect Dis 43:S216-23. 2006
    ..Review of the current state of knowledge regarding specific interactions between buprenorphine and antiretrovirals is followed by a review of the clinical applicability of these interactions...
  44. ncbi request reprint Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study
    Alison A Motsinger
    Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Pharmacogenet Genomics 16:837-45. 2006
    ..We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms...
  45. pmc Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories
    Diane T Holland
    Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group, Division of AIDS, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 48:824-31. 2004
    ..In conclusion, the PT program results presented demonstrate excellent interlaboratory agreement for all antiretrovirals tested and provide support for the merger of plasma concentration data among laboratories for large clinical trials...
  46. ncbi request reprint Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring
    Diane T Holland
    Pediatric Pharmacology Laboratory, University of California, San Diego, USA
    Ther Drug Monit 28:367-74. 2006
    ..The percentage of correct results is about the same as previously reported. There is a continued need for a PT program to help participating laboratories maintain essential quality assurance and quality control...
  47. ncbi request reprint HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries
    Charles C Maponga
    University of Zimbabwe College of Health Science, Avondale, Harare, Zimbabwe
    Top HIV Med 15:104-10. 2007
    ..The potential for the effective international collaboration is enhanced when expertise and resources from the developed world are combined with an understanding of the unique priorities of resource-limited settings...

Research Grants10